Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator—The PROLONG Study [Arrhythmia and Electrophysiology]

ConclusionsA relevant proportion of patients with newly diagnosed heart failure shows recovery of LVEF>35% beyond 3 months after initiation of heart failure therapy. To avoid untimely ICD implantation, prolongation of WCD period should be considered in these patients to prevent sudden cardiac death while allowing left ventricular reverse remodeling during intensified drug therapy.

Source: JAHA:Journal of the American Heart Association - January 17, 2017 Category: Cardiology Authors: Duncker, D., Konig, T., Hohmann, S., Bauersachs, J., Veltmann, C. Tags: Arrhythmias, Sudden Cardiac Death, Cardiomyopathy, Heart Failure Original Research Source Type: research